首頁 › 慢性淋巴性白血病 › 北卡羅來納州 › Durham
Durham, NC 的 慢性淋巴性白血病 臨床試驗
27 項針對 慢性淋巴性白血病 的研究正在 Durham（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
招募中3 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Durham VA Medical Center, Durham
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
招募中3 期
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
- University of North Carolina-Hillsborough Campus, Hillsborough · 距離 13 英里
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
招募中3 期
- Duke University Medical Center, Durham
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- University of North Carolina At Chapel Hill, Chapel Hill · 距離 10 英里
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- Duke University Medical Center, Durham
- University of North Carolina At Chapel Hill, Chapel Hill · 距離 10 英里
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- Duke University, Durham
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- Duke University, Durham
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
招募中2 期
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- UNC School of Medicine, Division of Hematology, Chapel Hill · 距離 10 英里
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
招募中2 期
- Research Site, Durham
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 距離 10 英里
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
招募中1 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距離 10 英里
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
招募中
- North Carolina Basnight Cancer Hospital, Chapel Hill · 距離 10 英里
Registry of Older Patients With Cancer
招募中觀察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距離 10 英里
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of North Carolina, Chapel Hill · 距離 10 英里
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Duke University Medical Center, Durham
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- Duke University, Durham
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
招募中2 期
- University of North Carolina /ID# 233313, Chapel Hill · 距離 10 英里
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
招募中2 期
- The University of North Carolina at Chapel Hill, Chapel Hill · 距離 10 英里
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
招募中1 期
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
招募中觀察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距離 10 英里
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
招募中2 期
- Durham VA Medical Center, Durham, NC, Durham
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- University of North Carolina, Chapel Hill · 距離 10 英里
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
招募中1 期
- Duke University, Durham
其他城市的 慢性淋巴性白血病 試驗
- Boston, MA31 項研究
- Columbus, OH28 項研究
- Washington, DC22 項研究
- Seattle, WA20 項研究
- Rochester, MN18 項研究
- New York City, NY18 項研究
- Houston, TX17 項研究
- Baldwin Park, CA16 項研究
- Milwaukee, WI15 項研究
- Chicago, IL14 項研究
- Cincinnati, OH14 項研究
- Nashville, TN13 項研究
Durham 的其他研究
- 乳癌64 項研究
- 癌症（所有類型）58 項研究
- 非小細胞肺癌39 項研究
- 多發性骨髓瘤37 項研究
- 急性髓系白血病33 項研究
- 轉移性癌症33 項研究
- 前列腺癌32 項研究
- 肺癌32 項研究
- 大腸直腸癌28 項研究
- 卵巢癌27 項研究
- 心臟衰竭26 項研究
- 胰臟癌24 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。